Literature DB >> 23421981

Plasmodium yoelii inhibitor of cysteine proteases is exported to exomembrane structures and interacts with yoelipain-2 during asexual blood-stage development.

Ying Pei1, Jessica L Miller1, Scott E Lindner1, Ashley M Vaughan1, Motomi Torii2, Stefan H I Kappe1,3.   

Abstract

Plasmodium falciparum (Pf) blood stages express falstatin, an inhibitor of cysteine proteases (ICP), which is implicated in regulating proteolysis during red blood cell infection. Recent data using the Plasmodium berghei rodent malaria model suggested an additional role for ICP in the infection of hepatocytes by sporozoites and during liver-stage development. Here we further characterize the role of ICP in vivo during infection with Plasmodium yoelii (Py) and Pf. We found that Py-ICP was refractory to targeted gene deletion indicating an essential function during asexual blood-stage replication, but significant downregulation of ICP using a regulated system did not impact blood-stage growth. Py-ICP localized to vesicles within the asexual blood-stage parasite cytoplasm, as well as the parasitophorous vacuole, and was exported to dynamic exomembrane structures in the infected RBC. In sporozoites, expression was observed in rhoptries, in addition to intracellular vesicles distinct from TRAP containing micronemes. During liver-stage development, Py-ICP was confined to the parasite compartment until the final phase of liver-stage development when, after parasitophorous vacuolemembrane breakdown, it was released into the infected hepatocyte. Finally, we identified the cysteine protease yoelipain-2 as a binding partner of Py-ICP during blood-stage infection. These data show that ICP may be important in regulating proteolytic processes during blood-stage development, and is likely playing a role in liver stage-hepatocyte interactions at the time of exoerythrocytic merozoite release.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23421981      PMCID: PMC3907115          DOI: 10.1111/cmi.12124

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  51 in total

1.  Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum.

Authors:  B R Shenai; P S Sijwali; A Singh; P J Rosenthal
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

2.  Myosin A tail domain interacting protein (MTIP) localizes to the inner membrane complex of Plasmodium sporozoites.

Authors:  Lawrence W Bergman; Karine Kaiser; Hisashi Fujioka; Isabelle Coppens; Thomas M Daly; Sarah Fox; Kai Matuschewski; Victor Nussenzweig; Stefan H I Kappe
Journal:  J Cell Sci       Date:  2003-01-01       Impact factor: 5.285

3.  Plasmodium falciparum cysteine protease falcipain-2 cleaves erythrocyte membrane skeletal proteins at late stages of parasite development.

Authors:  Manjit Hanspal; Meenakshi Dua; Yuichi Takakuwa; Athar H Chishti; Akiko Mizuno
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

4.  Ankyrin peptide blocks falcipain-2-mediated malaria parasite release from red blood cells.

Authors:  Shikha Dhawan; Meenakshi Dua; Athar H Chishti; Manjit Hanspal
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

5.  Stage-specific antimalarial activity of cysteine protease inhibitors.

Authors:  Bhaskar R Shenai; Andrey V Semenov; Philip J Rosenthal
Journal:  Biol Chem       Date:  2002-05       Impact factor: 3.915

6.  Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3.

Authors:  P S Sijwali; B R Shenai; J Gut; A Singh; P J Rosenthal
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

7.  Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum.

Authors:  Puran S Sijwali; Philip J Rosenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

8.  Evidence for trafficking of PfEMP1 to the surface of P. falciparum-infected erythrocytes via a complex membrane network.

Authors:  Hannes Wickert; Frank Wissing; Katherine T Andrews; August Stich; Georg Krohne; Michael Lanzer
Journal:  Eur J Cell Biol       Date:  2003-06       Impact factor: 4.492

9.  Antimalarial activities of novel synthetic cysteine protease inhibitors.

Authors:  Belinda J Lee; Ajay Singh; Peggy Chiang; Scott J Kemp; Erick A Goldman; Michael I Weinhouse; George P Vlasuk; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection.

Authors:  Mehdi Labaied; Anke Harupa; Ronald F Dumpit; Isabelle Coppens; Sebastian A Mikolajczak; Stefan H I Kappe
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

View more
  13 in total

Review 1.  Advances in molecular genetic systems in malaria.

Authors:  Tania F de Koning-Ward; Paul R Gilson; Brendan S Crabb
Journal:  Nat Rev Microbiol       Date:  2015-06       Impact factor: 60.633

2.  Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice.

Authors:  Sebastian A Mikolajczak; Ashley M Vaughan; Niwat Kangwanrangsan; Wanlapa Roobsoong; Matthew Fishbaugher; Narathatai Yimamnuaychok; Nastaran Rezakhani; Viswanathan Lakshmanan; Naresh Singh; Alexis Kaushansky; Nelly Camargo; Michael Baldwin; Scott E Lindner; John H Adams; Jetsumon Sattabongkot; Jetsumon Prachumsri; Stefan H I Kappe
Journal:  Cell Host Microbe       Date:  2015-03-19       Impact factor: 21.023

3.  Phosphoglycolate phosphatase is a metabolic proofreading enzyme essential for cellular function in Plasmodium berghei.

Authors:  Lakshmeesha Kempaiah Nagappa; Pardhasaradhi Satha; Thimmaiah Govindaraju; Hemalatha Balaram
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

Review 4.  Host cell remodeling by pathogens: the exomembrane system in Plasmodium-infected erythrocytes.

Authors:  Emma S Sherling; Christiaan van Ooij
Journal:  FEMS Microbiol Rev       Date:  2016-09       Impact factor: 16.408

5.  The Exported Chaperone PfHsp70x Is Dispensable for the Plasmodium falciparum Intraerythrocytic Life Cycle.

Authors:  David W Cobb; Anat Florentin; Manuel A Fierro; Michelle Krakowiak; Julie M Moore; Vasant Muralidharan
Journal:  mSphere       Date:  2017-09-27       Impact factor: 4.389

6.  South African Abietane Diterpenoids and Their Analogs as Potential Antimalarials: Novel Insights from Hybrid Computational Approaches.

Authors:  Thommas Musyoka; Özlem Tastan Bishop
Journal:  Molecules       Date:  2019-11-07       Impact factor: 4.411

7.  Inhibitor of cysteine proteases is critical for motility and infectivity of Plasmodium sporozoites.

Authors:  Katja E Boysen; Kai Matuschewski
Journal:  MBio       Date:  2013-11-26       Impact factor: 7.867

8.  A cysteine protease inhibitor of plasmodium berghei is essential for exo-erythrocytic development.

Authors:  Christine Lehmann; Anna Heitmann; Satish Mishra; Paul-Christian Burda; Mirko Singer; Monica Prado; Livia Niklaus; Céline Lacroix; Robert Ménard; Friedrich Frischknecht; Rebecca Stanway; Photini Sinnis; Volker Heussler
Journal:  PLoS Pathog       Date:  2014-08-28       Impact factor: 6.823

9.  Comparing sequence and structure of falcipains and human homologs at prodomain and catalytic active site for malarial peptide based inhibitor design.

Authors:  Thommas Mutemi Musyoka; Joyce Njoki Njuguna; Özlem Tastan Bishop
Journal:  Malar J       Date:  2019-05-03       Impact factor: 2.979

10.  Transcriptomics and proteomics reveal two waves of translational repression during the maturation of malaria parasite sporozoites.

Authors:  Scott E Lindner; Kristian E Swearingen; Stefan H I Kappe; Melanie J Shears; Michael P Walker; Erin N Vrana; Kevin J Hart; Allen M Minns; Photini Sinnis; Robert L Moritz
Journal:  Nat Commun       Date:  2019-10-31       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.